Suicidal ideation in depressed patients
Conditions
Interventions
Biparietal magnetic shock treatment group:Treatment of bilateral cerebral magnetic shock
Apex magnetic shock therapy group:Polar magnetic shock
Sponsors
Affiliated Kangning Hospital of Ningbo University
Eligibility
Sex/Gender
All
Age
18 Years to 55 Years
Inclusion criteria
Inclusion criteria: This study adheres to the Declaration of Helsinki and is approved by the hospital ethics committee in accordance with international medical ethics norms and standards. As a national clinical trial base for drugs (devices), our institution has rich experience in ethical review and strictly conducts reviews in accordance with requirements such as the "Measures for Ethical Review of Biomedical Research Involving Human Beings". After obtaining the informed consent of the individual and their family, they were included in this study. 1. Diagnosed as MDD according to the Fifth Edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5); 2. The baseline score on the 24-item Hamilton Depression Scale (HAMD-24) is greater than or equal to 18 points; 3. All patients were receiving MST treatment for the first time, and their attending psychiatrists had clinically evaluated that the patients met the indications for MST and determined that they were intended to receive MST treatment. During the trial treatment period, participants must use a single antidepressant at a stable dose. 5. Age between 18 and 55 years old; 6. Sign the informed consent form.
Exclusion criteria
Exclusion criteria: 1. Currently or previously suffering from organic brain diseases or neurological disorders; 2. There are contraindications to anesthesia, such as allergy to anesthetic drugs; 3. Currently taking antiepileptic drugs, benzodiazepines or other drugs that may affect the activity of epileptic seizures; 4. Have received MECT, transcranial magnetic stimulation (TMS), transcranial direct current stimulation (tDCS), or other treatments within the past six months 5. Those treated with cranial alternating current stimulation (tACS) or other nerve stimulation; 6. The presence of cochlear implants, pacemakers, other implantable medical devices or intracranial metals; 7. Pregnancy or lactation; 8. Participate in another clinical trial simultaneously; 9. Refuse to provide informed consent form; 10. Other circumstances where researchers consider participation inappropriate.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Clinical scale; | — |
Secondary
| Measure | Time frame |
|---|---|
| Brain region activation, functional connectivity, etc; | — |
Countries
China
Contacts
Public ContactChang Yu
Affiliated Kangning Hospital of Ningbo University
Outcome results
None listed